|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CYB5R4 |
Gene summary for CYB5R4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CYB5R4 | Gene ID | 51167 |
| Gene name | cytochrome b5 reductase 4 | |
| Gene Alias | NCB5OR | |
| Cytomap | 6q14.2 | |
| Gene Type | protein-coding | GO ID | GO:0002790 | UniProtAcc | Q7L1T6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51167 | CYB5R4 | LZE4T | Human | Esophagus | ESCC | 8.46e-15 | 3.62e-01 | 0.0811 |
| 51167 | CYB5R4 | LZE8T | Human | Esophagus | ESCC | 5.67e-03 | 9.15e-02 | 0.067 |
| 51167 | CYB5R4 | LZE24T | Human | Esophagus | ESCC | 1.42e-16 | 4.48e-01 | 0.0596 |
| 51167 | CYB5R4 | P2T-E | Human | Esophagus | ESCC | 1.61e-09 | 1.41e-01 | 0.1177 |
| 51167 | CYB5R4 | P4T-E | Human | Esophagus | ESCC | 5.14e-17 | 2.69e-01 | 0.1323 |
| 51167 | CYB5R4 | P5T-E | Human | Esophagus | ESCC | 1.34e-14 | 1.87e-01 | 0.1327 |
| 51167 | CYB5R4 | P8T-E | Human | Esophagus | ESCC | 1.71e-09 | 1.85e-01 | 0.0889 |
| 51167 | CYB5R4 | P9T-E | Human | Esophagus | ESCC | 1.50e-07 | 1.36e-01 | 0.1131 |
| 51167 | CYB5R4 | P10T-E | Human | Esophagus | ESCC | 4.89e-06 | 6.71e-02 | 0.116 |
| 51167 | CYB5R4 | P11T-E | Human | Esophagus | ESCC | 2.37e-12 | 4.97e-01 | 0.1426 |
| 51167 | CYB5R4 | P12T-E | Human | Esophagus | ESCC | 4.29e-12 | 1.86e-01 | 0.1122 |
| 51167 | CYB5R4 | P15T-E | Human | Esophagus | ESCC | 2.31e-12 | 3.13e-01 | 0.1149 |
| 51167 | CYB5R4 | P16T-E | Human | Esophagus | ESCC | 1.41e-06 | 5.53e-02 | 0.1153 |
| 51167 | CYB5R4 | P19T-E | Human | Esophagus | ESCC | 8.94e-06 | 3.52e-01 | 0.1662 |
| 51167 | CYB5R4 | P20T-E | Human | Esophagus | ESCC | 1.49e-11 | 2.44e-01 | 0.1124 |
| 51167 | CYB5R4 | P21T-E | Human | Esophagus | ESCC | 1.65e-17 | 3.97e-01 | 0.1617 |
| 51167 | CYB5R4 | P22T-E | Human | Esophagus | ESCC | 1.36e-06 | 8.75e-02 | 0.1236 |
| 51167 | CYB5R4 | P23T-E | Human | Esophagus | ESCC | 4.74e-17 | 4.85e-01 | 0.108 |
| 51167 | CYB5R4 | P24T-E | Human | Esophagus | ESCC | 5.22e-12 | 2.97e-01 | 0.1287 |
| 51167 | CYB5R4 | P26T-E | Human | Esophagus | ESCC | 7.54e-15 | 3.25e-01 | 0.1276 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006091110 | Esophagus | ESCC | generation of precursor metabolites and energy | 331/8552 | 490/18723 | 3.86e-23 | 8.45e-21 | 331 |
| GO:0070482111 | Esophagus | ESCC | response to oxygen levels | 218/8552 | 347/18723 | 6.91e-11 | 2.17e-09 | 218 |
| GO:007259318 | Esophagus | ESCC | reactive oxygen species metabolic process | 137/8552 | 239/18723 | 1.82e-04 | 1.16e-03 | 137 |
| GO:00466774 | Esophagus | ESCC | response to antibiotic | 34/8552 | 47/18723 | 1.91e-04 | 1.21e-03 | 34 |
| GO:000930617 | Esophagus | ESCC | protein secretion | 190/8552 | 359/18723 | 3.22e-03 | 1.34e-02 | 190 |
| GO:003559217 | Esophagus | ESCC | establishment of protein localization to extracellular region | 190/8552 | 360/18723 | 3.77e-03 | 1.53e-02 | 190 |
| GO:007169210 | Esophagus | ESCC | protein localization to extracellular region | 193/8552 | 368/18723 | 5.01e-03 | 1.92e-02 | 193 |
| GO:000609118 | Oral cavity | OSCC | generation of precursor metabolites and energy | 286/7305 | 490/18723 | 1.45e-18 | 1.71e-16 | 286 |
| GO:007048219 | Oral cavity | OSCC | response to oxygen levels | 200/7305 | 347/18723 | 1.17e-12 | 5.13e-11 | 200 |
| GO:00466773 | Oral cavity | OSCC | response to antibiotic | 32/7305 | 47/18723 | 5.11e-05 | 4.27e-04 | 32 |
| GO:007259316 | Oral cavity | OSCC | reactive oxygen species metabolic process | 122/7305 | 239/18723 | 9.73e-05 | 7.34e-04 | 122 |
| GO:000930610 | Oral cavity | OSCC | protein secretion | 169/7305 | 359/18723 | 1.04e-03 | 5.34e-03 | 169 |
| GO:004259316 | Oral cavity | OSCC | glucose homeostasis | 125/7305 | 258/18723 | 1.21e-03 | 6.08e-03 | 125 |
| GO:003559210 | Oral cavity | OSCC | establishment of protein localization to extracellular region | 169/7305 | 360/18723 | 1.21e-03 | 6.08e-03 | 169 |
| GO:00716929 | Oral cavity | OSCC | protein localization to extracellular region | 172/7305 | 368/18723 | 1.40e-03 | 6.79e-03 | 172 |
| GO:003350016 | Oral cavity | OSCC | carbohydrate homeostasis | 125/7305 | 259/18723 | 1.44e-03 | 6.97e-03 | 125 |
| GO:0006091111 | Skin | cSCC | generation of precursor metabolites and energy | 224/4864 | 490/18723 | 1.13e-21 | 2.21e-19 | 224 |
| GO:007048226 | Skin | cSCC | response to oxygen levels | 133/4864 | 347/18723 | 2.39e-07 | 5.07e-06 | 133 |
| GO:007259319 | Skin | cSCC | reactive oxygen species metabolic process | 81/4864 | 239/18723 | 3.80e-03 | 2.03e-02 | 81 |
| GO:004667713 | Skin | cSCC | response to antibiotic | 21/4864 | 47/18723 | 4.20e-03 | 2.21e-02 | 21 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa005202 | Esophagus | ESCC | Amino sugar and nucleotide sugar metabolism | 35/4205 | 49/8465 | 1.60e-03 | 4.88e-03 | 2.50e-03 | 35 |
| hsa0052011 | Esophagus | ESCC | Amino sugar and nucleotide sugar metabolism | 35/4205 | 49/8465 | 1.60e-03 | 4.88e-03 | 2.50e-03 | 35 |
| hsa00520 | Oral cavity | OSCC | Amino sugar and nucleotide sugar metabolism | 34/3704 | 49/8465 | 2.48e-04 | 8.08e-04 | 4.11e-04 | 34 |
| hsa005201 | Oral cavity | OSCC | Amino sugar and nucleotide sugar metabolism | 34/3704 | 49/8465 | 2.48e-04 | 8.08e-04 | 4.11e-04 | 34 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CYB5R4 | SNV | Missense_Mutation | c.227N>C | p.Arg76Thr | p.R76T | Q7L1T6 | protein_coding | deleterious(0.02) | probably_damaging(0.916) | TCGA-A8-A075-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | CR | |
| CYB5R4 | SNV | Missense_Mutation | c.1341N>G | p.Asp447Glu | p.D447E | Q7L1T6 | protein_coding | tolerated(0.22) | benign(0.02) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| CYB5R4 | SNV | Missense_Mutation | rs749995161 | c.869N>T | p.Thr290Met | p.T290M | Q7L1T6 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-C8-A1HI-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CYB5R4 | deletion | Frame_Shift_Del | rs745836350 | c.734delN | p.Glu248ArgfsTer12 | p.E248Rfs*12 | Q7L1T6 | protein_coding | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CYB5R4 | insertion | Frame_Shift_Ins | novel | c.1228_1229insGG | p.Asn410ArgfsTer5 | p.N410Rfs*5 | Q7L1T6 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
| CYB5R4 | insertion | Nonsense_Mutation | novel | c.1229_1230insGTAACAGTATAAATAC | p.Asn410LysfsTer2 | p.N410Kfs*2 | Q7L1T6 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
| CYB5R4 | SNV | Missense_Mutation | novel | c.570N>G | p.Ile190Met | p.I190M | Q7L1T6 | protein_coding | tolerated(0.58) | benign(0.007) | TCGA-C5-A8XK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| CYB5R4 | SNV | Missense_Mutation | novel | c.670N>A | p.Glu224Lys | p.E224K | Q7L1T6 | protein_coding | tolerated(0.25) | benign(0.328) | TCGA-UC-A7PG-06 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
| CYB5R4 | SNV | Missense_Mutation | c.503N>A | p.Pro168Gln | p.P168Q | Q7L1T6 | protein_coding | deleterious(0.01) | benign(0.305) | TCGA-AA-3852-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| CYB5R4 | SNV | Missense_Mutation | c.530C>A | p.Ser177Tyr | p.S177Y | Q7L1T6 | protein_coding | tolerated(0.05) | possibly_damaging(0.707) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 51167 | CYB5R4 | DRUGGABLE GENOME | rasburicase | RASBURICASE | ||
| 51167 | CYB5R4 | DRUGGABLE GENOME | primaquine | PRIMAQUINE | ||
| 51167 | CYB5R4 | DRUGGABLE GENOME | isosorbide mononitrate | |||
| 51167 | CYB5R4 | DRUGGABLE GENOME | metoclopramide | METOCLOPRAMIDE | ||
| 51167 | CYB5R4 | DRUGGABLE GENOME | isosorbide dinitrate |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |